Alps Group Expands Exosome Pipeline Beyond CELESOME(+) Following Asthma and COPD Study Publication.

Alps Group Inc has announced a potential expansion of its exosome-related pipeline beyond the CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series describing nebulized human umbilical cord mesenchymal stem cell-derived exosome therapy in patients with asthma and/or COPD. The study reports promising improvements in pulmonary function and stability in inflammatory markers with no significant adverse effects.